Cubist Systematic Strategies LLC Takes $5.73 Million Position in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Cubist Systematic Strategies LLC recently acquired a $5.73 million stake in Amneal Pharmaceuticals, purchasing 684,116 shares, which amounted to approximately 0.22% of the company's total stock.
• Multiple institutional investors, including Janney Montgomery Scott LLC and Allspring Global Investments, have increased their positions in Amneal Pharmaceuticals substantially during the first quarter.
• Amneal Pharmaceuticals has received a consensus rating of "Buy" from analysts, with an average target price of $11.60, despite recent downgrades from a "strong-buy" rating.

Cubist Systematic Strategies LLC acquired a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 684,116 shares of the company's stock, valued at approximately $5,733,000. Cubist Systematic Strategies LLC owned 0.22% of Amneal Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Janney Montgomery Scott LLC lifted its stake in shares of Amneal Pharmaceuticals by 26.9% in the 1st quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company's stock valued at $162,000 after purchasing an additional 4,100 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Amneal Pharmaceuticals by 53.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company's stock valued at $508,000 after purchasing an additional 21,079 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Amneal Pharmaceuticals by 45.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock valued at $2,522,000 after purchasing an additional 99,866 shares during the period. California State Teachers Retirement System lifted its stake in shares of Amneal Pharmaceuticals by 10.3% in the 4th quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock valued at $1,043,000 after purchasing an additional 12,282 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of Amneal Pharmaceuticals by 209.2% in the 4th quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock valued at $1,332,000 after purchasing an additional 113,796 shares during the period. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently issued reports on AMRX shares. Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They set a "buy" rating and a $12.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals has a consensus rating of "Buy" and an average target price of $11.60.

Insider Buying and Selling

In other news, EVP Jason B. Daly sold 22,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total value of $199,100.00. Following the completion of the sale, the executive vice president directly owned 10,606 shares of the company's stock, valued at $95,984.30. This represents a 67.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director John Kiely sold 32,000 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $9.23, for a total value of $295,360.00. Following the completion of the sale, the director directly owned 225,433 shares of the company's stock, valued at approximately $2,080,746.59. This trade represents a 12.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 609,206 shares of company stock valued at $5,700,625. 17.45% of the stock is owned by company insiders.

Amneal Pharmaceuticals Stock Performance

AMRX stock opened at $9.54 on Thursday. The stock's 50 day simple moving average is $8.62 and its 200 day simple moving average is $8.10. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.68 and a fifty-two week high of $9.79. The company has a market cap of $3.00 billion, a P/E ratio of 954.95 and a beta of 1.19.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. Equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.